Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults
Obesity · 2026
DOI: 10.1002/oby.70218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Jie-Syuan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Osteoporosis, Anti-Obesity Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Methods
This retrospective cohort study included deidentified TriNetX data on ≥ 50‐year‐old nondiabetic adults with obesity. After 1:1 propensity score matching on demographic, clinical, and laboratory covariates, 18,062 GLP‐1 RA users were compared with non‐GLP‐1 medication users. The primary outcome was incident osteoporosis; secondary outcomes included major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis.
Results
GLP‐1 RA use was associated with lower risks of osteoporosis (relative risk [RR] 0.48; 95% CI, 0.43–0.52; number needed to treat [NNT] = 28), major osteoporotic fractures (RR 0.15; 95% CI, 0.11–0.22; NNT = 88), cervical disc degeneration (RR 0.34; 95% CI, 0.28–0.41; NNT = 63), thoracolumbar disc disease (RR 0.36; 95% CI, 0.33–0.40; NNT = 20), and osteoarthritis (RR 0.45; 95% CI, 0.43–0.48; NNT = 9). Protective associations were consistent across age, sex, BMI, and drug subtype subgroups and remained robust in sensitivity analyses.
Conclusions
GLP‐1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
- School of Nutrition, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
- School of Food Safety, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Jie-Syuan Wu, Lee-Yuan Lin, Jia-Wei Sun, Fara Silvia Yuliani, Shyh-Hsiang Lin
Zitieren
APA
Wu, J. S., Lin, L. Y., Sun, J. W., Yu, W. T., Yuliani, F. S., & Lin, S. H. (2026). Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Obesity. https://doi.org/10.1002/oby.70218
Vancouver
Wu JS, Lin LY, Sun JW, Yu WT, Yuliani FS, Lin SH. Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Obesity. 2026. doi:10.1002/oby.70218
BibTeX
@article{Wu2026,
author = {Wu, Jie-Syuan and Lin, Lee-Yuan and Sun, Jia-Wei and Yu, Wei-Ting and Yuliani, Fara Silvia and Lin, Shyh-Hsiang},
title = {Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70218}
}
EUVIMED